Research programme: fibroblast growth factor receptor inhibitors - Cogent Biosciences
Alternative Names: FGFR2 inhibitors - Cogent BiosciencesLatest Information Update: 08 Nov 2023
At a glance
- Originator Cogent Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Type-2 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer